Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#2981 The Distance from Pathology to Molecular Imaging: SSTR Expression Comparison in 100 Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: Somatostatin receptor (SSTR) overexpression is a unique feature of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establish the basis for both diagnosis and therapy. SSTR status can be evaluated by immunohistochemical staining (IHC) and 68Ga-DOTATATE PET/CT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yu J

Authors: Yu J, Cao F, Yang Z, Sun Y,

Keywords: GEP-NEN, SSTR, PET/CT, IHC,

#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.

Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Brizzi M, Sonetto C, Bitossi R, Baratelli C, Volante M,

Keywords: Bronchial carcinoid, everolimus, hemodialysis,

#1221 Pancreatic Location, High Proliferation and Low p-mTOR Expression Levels Are More Frequent in Neuroendocrine Tumor Patients Responsive to mTOR Inhibitors: Results from a Preliminary Study

Introduction: MTOR inhibitors are approved for the treatment of advanced neuroendocrine tumors. However, scarce data are available on clinical or pathological predictors of response to these agents

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Volante M

Authors: Birocco N, Brizzi M, Airoldi M, De Angelis C, Ciuffreda L,

Keywords: mTOR inhibitor, biomarker,

#1131 M-TORC1 Complex Is Significantly Over-Activated in SDHx-Mutated Paragangliomas

Introduction: The activation patterns of mTOR pathway in sporadic and hereditary pheochromocytomas (PCC) and paragangliomas (PGL) are poorly recognized.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Volante M

Authors: Oudijk L, Papathomas T, De Krijger R, Gimenez-Roqueplo A, Mannelli M,

Keywords: PCC, PGL, mTOR, SDHx,

#954 Specific MicroRNA Profiles are Associated with Pathological Features in Lung Carcinoids

Introduction: Data on miRNA expression in lung carcinoids are scarce.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Volante M

Authors: Rapa I, Votta A, Felice B, Righi L, Giorcelli J,

Keywords: lung, carcinoid, miRNA,